Advertisement

Novel vaccination strategies

  • Maria Lattanzi
  • Rino Rappuoli
Chapter
  • 527 Downloads
Part of the Birkhäuser Advances in Infectious Diseases BAID book series (BAID)

Keywords

Haemophilus Influenzae Conjugate Vaccine Vaccination Strategy Pertussis Vaccine Neisseria Meningitidis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Glenny AT, Hopkins BE (1923) Diphtheria toxoid as an immunizing agent. Br J Exp Pathol 4: 283–288Google Scholar
  2. 2.
    Ramon G (1923) Sur le pouvoir floculant et sur les propriétés immunisantes d’une toxine diphthérique rendue anatoxique (anatoxine). CR Acad Sci (Paris) 177: 1338–1340Google Scholar
  3. 3.
    Ramon G (1925) Sur la production des antitoxins. CR Acad Sci (Paris) 181: 157–159Google Scholar
  4. 4.
    Ehreth J (2003) The global value of vaccination. Vaccine 21: 596–600PubMedGoogle Scholar
  5. 5.
    World Health Organization, Fact sheet N.114, Poliomyelitis, revised April 2003, accessed May 2004: http://www.who.int/mediacentre/factsheets/fs114/en/Google Scholar
  6. 6.
    Jodar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359: 1499–1508PubMedCrossRefGoogle Scholar
  7. 7.
    Morley SL, Pollard AJ (2002) Vaccine prevention of meningococcal disease, coming soon? Vaccine 20: 666–687Google Scholar
  8. 8.
    Wenger JD, Ward JI (2004) Haemophilus influenzae vaccine. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth Edition, Saunders, Philadelphia, 229–268Google Scholar
  9. 9.
    Wuorimaa T, Kayhty H (2002) Current state of pneumococcal vaccines. Scand J Immunol 56: 111–129PubMedCrossRefGoogle Scholar
  10. 10.
    Plotkin SA, Bouveret-Le Cam N (1995) A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 155: 2293–2299PubMedCrossRefGoogle Scholar
  11. 11.
    Wenger J, Campbell H, Miller E., Salisbury D (2004) The postlicensure impact of Haemophilus influenzae type b and serogroup C Neisseria meningitidis conjugate vaccines. In: MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (eds): New generation vaccines. Third Edition. Marcel Dekker, New York, 427–441Google Scholar
  12. 12.
    Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13: 302–317PubMedCrossRefGoogle Scholar
  13. 13.
    Cochi SL, Broome CV, Hightower AW (1985) Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA 253: 521–529PubMedCrossRefGoogle Scholar
  14. 14.
    CDC (2004) Summary of notifiable diseases, United States, 2002. MMWR, Published April 30, 2004 for 2002 51(53): 8Google Scholar
  15. 15.
    Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, Makela PH (1991) Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 164: 982–986PubMedGoogle Scholar
  16. 16.
    Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM (1993) Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 122: 517–523PubMedGoogle Scholar
  17. 17.
    Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER (1995) The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 171: 93–98PubMedGoogle Scholar
  18. 18.
    Forleo-Neto E, de Oliveira CF, Maluf EM, Bataglin C, Araujo JM, Kunz LF Jr, Pustai AK, Vieira VS, Zanella RC, Brandileone MC et al (1999) Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis 180: 1153–1158PubMedCrossRefGoogle Scholar
  19. 19.
    Lipsitch M (1997) Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 94: 6571–6576PubMedCrossRefGoogle Scholar
  20. 20.
    Lipsitch M (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5: 336–345PubMedCrossRefGoogle Scholar
  21. 21.
    Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M, Salgado K, Silva HR, Zanella RC, Almeida SC et al (2003) Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 187: 1109–1116CrossRefGoogle Scholar
  22. 22.
    Lucher LA, Reeves M, Hennessy T, Levine OS, Popovic T, Rosenstein N, Parkinson AJ (2002) Reemergence, in Southwestern Alaska, of invasive Haemophilus influenzae type b disease due to strains indistinguishable from those isolated from vaccinated children. J Infect Dis 187: 958–965Google Scholar
  23. 23.
    Siber GR (1994) Pneumococcal disease: prospects for a new generation of vaccines. Science 265: 1385–1387PubMedGoogle Scholar
  24. 24.
    Levine O, Klein DL, Butler JC (2004) Pneumococcal protein-polysaccharide conjugate vaccines. In: MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (eds): New generation vaccines. Third edition. Marcel Dekker, New York, 443–457Google Scholar
  25. 25.
    Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J et al (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729–1735PubMedGoogle Scholar
  26. 26.
    Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I. Clin Infect Dis 30: 100–121PubMedGoogle Scholar
  27. 27.
    CDC (2000) Prevention of pneumococcal disease among infants and young children using a pneumococcal conjugate vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 49(RR-9): 1–35Google Scholar
  28. 28.
    Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G et al (2000) Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187–195PubMedGoogle Scholar
  29. 29.
    Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R et al (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344: 403–409PubMedCrossRefGoogle Scholar
  30. 30.
    Eskola J, Black S, Shinefield H (2004) Pneumococcal conjugate vaccines. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth edition, Saunders, Philadelphia, 589–624Google Scholar
  31. 31.
    Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R (1992) Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10(10): 691–698PubMedCrossRefGoogle Scholar
  32. 32.
    Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakeh H, Pais L, Holder P, Carlone GM (1994) Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 62(8): 3391–3395PubMedGoogle Scholar
  33. 33.
    Twumasi PA Jr, Kumah S, Leach A, O’Dempsey TJ, Ceesay SJ, Todd J, Broome CV, Carlone GM, Pais LB, Holder PK et al (1995) A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171(3): 632–638PubMedGoogle Scholar
  34. 34.
    Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI (1996) Safety and immunogenicity of a serogroups A:C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 275(19): 1499–1503PubMedCrossRefGoogle Scholar
  35. 35.
    Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K (1996) Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 174(6): 1360–1363PubMedGoogle Scholar
  36. 36.
    Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, Granoff DM, LiButti DE, Carlone GM, Pais LB et al (1997) Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysacchairde-protein conjugate vaccine. J Infect Dis 175(1): 200–204PubMedGoogle Scholar
  37. 37.
    MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM et al (1998) Induction of immunologic mamory by conjugated vs plain meningococcal C polysaccharide vaccines in toddlers: a randomized controlled trial. JAMA 280: 1685–1689PubMedCrossRefGoogle Scholar
  38. 38.
    Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K et al (1999) Meningococcal group C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179: 1569–1572PubMedCrossRefGoogle Scholar
  39. 39.
    Borrow R, Fox AJ, Richmond PC, Clark S, Sadler F, Findlow J, Morris R, Begg NT, Cartwright KA et al (2000) Induction of immunological memory in UK infants by a meningococcal AC conjugate vaccine. Epidemiol Infect 124(3): 427–432PubMedCrossRefGoogle Scholar
  40. 40.
    Miller E, Salisbury D, Ramsay M (2001) Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1): S58–S67PubMedGoogle Scholar
  41. 41.
    Ramsay M, Andrews N, Kacmarski EB, Miller E (2001) Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357: 195–196PubMedGoogle Scholar
  42. 42.
    Maiden MC, Stuart JM, UK Meningococcal Carriage Group (2002) Reduced carriage of serogroup C meningococci in teenagers one year after the introduction of meningococcal C conjugate vaccine in the United Kingdom. Lancet 359: 1829–1831PubMedCrossRefGoogle Scholar
  43. 43.
    Balmer P, Borrow R, Miller E (2002) Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51: 717–722PubMedGoogle Scholar
  44. 44.
    Granoff DM, Feavers IM, Borrow R (2004) Meningococcal vaccines. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth edition, Saunders, Philadelphia, 959–987Google Scholar
  45. 45.
    Rappuoli R, Pollard AJ, Moxon R (2004) Meningococcal conjugate and protein-based vaccines. In: MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (eds): New generation vaccines. Third edition. Marcel Dekker, New York, 421–426Google Scholar
  46. 46.
    Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the US. N Engl J Med 303: 833–841PubMedCrossRefGoogle Scholar
  47. 47.
    Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 347–350PubMedCrossRefGoogle Scholar
  48. 48.
    Coates T, Wilson R, Patrick G, Andre F, Watson V (2001) Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 23: 392–403PubMedCrossRefGoogle Scholar
  49. 49.
    Andre FE (1990) Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 8(Suppl): S74–S78PubMedGoogle Scholar
  50. 50.
    Clements ML, Miskovsky E, Davidson M, Cupps T, Kumwenda N, Sandman LA, West D, Hesley T, Ioli V, Miller W et al (1994) Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen S or PreS2 + S antigens. J Infect Dis 170: 510–516PubMedGoogle Scholar
  51. 51.
    Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, Safary A (1992) Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 11: 816–821PubMedGoogle Scholar
  52. 52.
    Arevalo JA, Washington E (1988) Cost effectiveness of perinatal screening and immunization for hepatitis B virus. JAMA 259: 365–369PubMedCrossRefGoogle Scholar
  53. 53.
    World Health Organization (1992) Expanded program on immunization global advisory group. Wk Epidemiol Rec 3: 11–16Google Scholar
  54. 54.
    Mast E, Mahoney F, Kane M, Margolis H (2004) Hepatitis B vaccine. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth edition, Saunders, Philadelphia, 299–337Google Scholar
  55. 55.
    Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS (2003) Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 187: 134–138PubMedCrossRefGoogle Scholar
  56. 56.
    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855–1859PubMedCrossRefGoogle Scholar
  57. 57.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21): 1645–1651PubMedCrossRefGoogle Scholar
  58. 58.
    Del Giudice G, Covacci A, Telford J, Montecucco C, Rappuoli R (2001) The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19: 523–563PubMedGoogle Scholar
  59. 59.
    Kendrick PL, Eldering G, Dixon MK (1947) Mouse protection tests in the study of pertussis vaccine: a comparative study using intracerebral route for challenge. Am J Publ Health 37: 803CrossRefGoogle Scholar
  60. 60.
    National Bacteriological Laboratory, Sweden (1988) A clinical trial of acellular pertussis vaccine in Sweden. Technical Report 1988, Stockholm.Google Scholar
  61. 61.
    Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M et al (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246: 497–500PubMedGoogle Scholar
  62. 62.
    Podda A, Nencioni L, De Magistris MT, Di Tommaso A, Bossu P, Nuti S, Pileri P, Peppoloni S, Bugnoli M, Ruggiero P et al (1990) Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med 172: 861–868PubMedCrossRefGoogle Scholar
  63. 63.
    Podda A, De Luca EC, Titone L, Casadei AM, Cascio A, Peppoloni S, Volpini G, Marsili I, Nencioni L, Rappuoli R (1992) Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12-to 24-and 2-to 4-month-old children. J Pediatr 120: 680–685PubMedGoogle Scholar
  64. 64.
    Podda A, Nencioni L, Marsili I, Peppoloni S, Volpini G, Donati D, Di Tommaso A, De Magistris MT, Rappuoli R (1991) Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9: 741–745PubMedCrossRefGoogle Scholar
  65. 65.
    Podda A, Carapella De Luca E, Titone L, Casadei AM, Cascio A, Bartalini M, Volpini G, Marsili I, Nencioni L, Rappuoli R (1993) Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. J Pediatr 123: 81–84PubMedGoogle Scholar
  66. 66.
    Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC et al (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 334(6): 341–348PubMedCrossRefGoogle Scholar
  67. 67.
    Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350(9091): 1569–1577PubMedCrossRefGoogle Scholar
  68. 68.
    Di Tommaso A, Bartalini M, Peppoloni S, Podda A, Rappuoli R, De Magistris MT (1997) Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 15: 1218–1224PubMedGoogle Scholar
  69. 69.
    Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A, Stage III Working Group (2001) Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108, E81PubMedCrossRefGoogle Scholar
  70. 70.
    Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM et al (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269: 496–512PubMedGoogle Scholar
  71. 71.
    Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19: 2688–2691PubMedGoogle Scholar
  72. 72.
    Mora M, Veggi D, Santini L, Pizza M (2003) Reverse vaccinology. Drug Discovery Today 8(10): 459–464PubMedCrossRefGoogle Scholar
  73. 73.
    Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B et al (2000) Whole genome sequencing to identify vaccine candidates against serogroup B meningococcus. Science 287: 1816–1820PubMedCrossRefGoogle Scholar
  74. 74.
    Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J et al (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomised controlled trial in Chile. JAMA 281: 1520–1527PubMedCrossRefGoogle Scholar
  75. 75.
    Adu-Bobie J, Capecchi B, Serruto D (2003) Two years into reverse vaccinology. Vaccine 21: 605–610PubMedCrossRefGoogle Scholar
  76. 76.
    Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, Barash SC, Rosen CA, Masure HR, Tuomanen E et al (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69: 1593–1598PubMedCrossRefGoogle Scholar
  77. 77.
    Schuchat A (1999) Group B streptococcus. Lancet 353: 51–56PubMedCrossRefGoogle Scholar
  78. 78.
    Paoletti LC, Kasper DL (2002) Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis 186(1): 123–126PubMedCrossRefGoogle Scholar
  79. 79.
    Tettelin H, Masignani V, Cieslewicz MJ, Eisen JA, Peterson S, Wessels MR, Paulsen IT, Nelson KE, Margarit I, Read TD et al (2002) Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 99: 12391–12396PubMedCrossRefGoogle Scholar
  80. 80.
    Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Sollner J, Schmidt W, von Ahsen U et al (2002) Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99(10): 6573–6578PubMedCrossRefGoogle Scholar
  81. 81.
    The American Academy of Periodontology (1999) The pathogenesis of periodontal diseases. J Periodontol 70: 457–470Google Scholar
  82. 82.
    Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, Rothel L, Patterson M, Agius C, Camuglia S, Reynolds E et al (2001) Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19(30): 4135–4142PubMedCrossRefGoogle Scholar
  83. 83.
    Grayston JT (2000) Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181(Suppl 3): S402–S410PubMedGoogle Scholar
  84. 84.
    Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R et al (2002) Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70(1): 368–379PubMedCrossRefGoogle Scholar
  85. 85.
    Brachman PS, Friedlander AM, Grabenstein JD (2004) Anthrax vaccine. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth edition, Saunders, Philadelphia, 887–903Google Scholar
  86. 86.
    Cieslak TJ, Kortepeter MG, Eitzen EM (2004) Vaccines against agents of bioterrorism. In: MM Levine, JB Kaper, R Rappuoli, MA Liu, MB Good (eds): New generation vaccines. Third edition. Marcel Dekker, New York, 1067–1079Google Scholar
  87. 87.
    Ariel N, Zvi A, Grosfeld H, Gat O, Inbar Y, Velan B, Cohen S, Shafferman A (2002) Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun 70: 6817–6827PubMedCrossRefGoogle Scholar
  88. 88.
    Titball RW, Williamson ED, Dennis DT (2004) Plague. In: SA Plotkin, WA Orenstein (eds): Vaccines. Fourth edition, Saunders, Philadelphia, 999–1010Google Scholar
  89. 89.
    Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, Gur D, Lazar S, Zvi A, Bino T, Ariel N et al (2004) Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect Immun 72(2): 908–915PubMedCrossRefGoogle Scholar
  90. 90.
    Peiris JS, Phil D, Yuen KY (2003) The severe acute respiratory syndrome. N Engl J Med 349: 2431–2441PubMedCrossRefGoogle Scholar
  91. 91.
    Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH et al (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394–1399PubMedCrossRefGoogle Scholar
  92. 92.
    Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY et al (2003) The genome sequence of the SARS-associated coronavirus. Science 300: 1399–1404PubMedCrossRefGoogle Scholar
  93. 93.
    Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R (2003) Sars — beginning to understand a new virus. Nat Rev Microbiol 1: 209–218PubMedCrossRefGoogle Scholar
  94. 94.
    CDC (1998) Impact of vaccines universally recommended for children — US, 1990–98. MMWR 48: 577–581Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Maria Lattanzi
    • 1
  • Rino Rappuoli
    • 1
  1. 1.Chiron VaccinesSienaItaly

Personalised recommendations